SCHEMBL25430237

SCHEMBL25430237

CC(C)(C)OC(=O)N1CCc2[nH]nc(C(N)=O)c2C1

nearest known ligand 0.61

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
ADORA1 P30542 2/20 0.43
NR1H2 P55055 1/20 0.43
RBP4 P02753 3/20 0.41
ESR2 Q92731 1/20 0.41
MAP3K14 Q99558 1/20 0.39
C5AR1 P21730 1/20 0.38
MAPK1 P28482 2/20 0.38
KDM4E B2RXH2 1/20 0.38
MAPT P10636 1/20 0.38
F12 P00748 1/20 0.38
CREBBP Q92793 3/20 0.37
BRD4 O60885 2/20 0.37
EP300 Q09472 2/20 0.37
PARP1 P09874 1/20 0.37
TNKS2 Q9H2K2 1/20 0.37
PARP2 Q9UGN5 1/20 0.37
NAMPT P43490 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14520683 0.89 ESR2 (0.41) ADORA1NR1H2RBP4ESR2MAPK1
SCHEMBL4792110 0.89 ADORA1 (0.46) ADORA1NR1H2RBP4ESR2MAPK1
SCHEMBL17878107 0.86 MAPK1 (0.42) ADORA1NR1H2RBP4ESR2MAPK1
SCHEMBL29386147 0.85 RBP4 (0.42) ADORA1NR1H2RBP4ESR2MAPK1
SCHEMBL1888941 0.85 ADORA1 (0.47) ADORA1NR1H2ESR2MAPK1KDM4E
SCHEMBL17870541 0.84 RBP4 (0.39) ADORA1NR1H2RBP4ESR2MAPK1
SCHEMBL4761427 0.83 ADORA1 (0.51) ADORA1NR1H2RBP4ESR2MAPT
SCHEMBL4761735 0.83 RBP4 (0.42) ADORA1NR1H2RBP4ESR2MAPK1
SCHEMBL17870535 0.83 RBP4 (0.39) ADORA1NR1H2RBP4ESR2MAPK1
SCHEMBL17868654 0.83 ESR2 (0.46) ADORA1NR1H2ESR2MAPK1MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4466258-A1 NEW BENZIMIDAZOLE PYRIDINE DERIVATIVES F. Hoffmann-La Roche AG (CH) 2024-11-27 EP disclosed
US-20240383875-A1 Benzimidazole Pyridine Derivatives HOFFMANN-LA ROCHE INC. (US) 2024-11-21 US disclosed
CN-118591534-A Novel benzimidazole pyridine derivatives 豪夫迈·罗氏有限公司 2024-09-03 CN disclosed
WO-2023139085-A1 NEW BENZIMIDAZOLE PYRIDINE DERIVATIVES F. HOFFMANN-LA ROCHE AG (CH) 2023-07-27 WO disclosed
WO-2023139085-A1 NEW BENZIMIDAZOLE PYRIDINE DERIVATIVES F. HOFFMANN-LA ROCHE AG (CH) 2023-07-27 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240383875-A1 Benzimidazole Pyridine Derivatives H1-3, H1-2, H1-4 ADORA1 9/4885NR1H2 3335/4885RBP4 3298/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.